Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 5 September 2025 – 5:40 PM CET Disclosure of notification received from Mawer Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from Mawer. Notification by Mawer Investment Management Ltd On 3 September 2025, Fagron received a notification that the shareholding of Mawer Investment Management Ltd, crossed the disclosure threshold of 5% downwards on ...

Core Points - Fagron received a notification from Alychlo NV regarding a change in shareholding that crossed the disclosure threshold of 3% downwards [1][8] - The notification indicates that Alychlo NV disposed of voting securities or voting rights on 25 July 2024, resulting in a new holding of 2,139,886 voting rights [8] - The total number of voting rights at that time was 73,228,904, meaning Alychlo NV and Marc Coucke together held 2.93% of the total voting rights [8] Company Information - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 30 countries [3] - The company is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Operational activities are managed by Fagron BV, headquartered in Rotterdam [4]

Group 1 - Fagron has issued 85,000 new shares as a result of the exercise of subscription rights on June 6, 2025 [1] - The total share capital of Fagron currently amounts to €504,303,905.59, with a total of 73,313,904 shares with voting rights [2] - There are 1,465,833 rights to subscribe to not yet issued shares with voting rights [2] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to various healthcare facilities in 35 countries [3] - The company is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Fagron's operational activities are managed by its Dutch subsidiary, Fagron BV, headquartered in Rotterdam [4]

Group 1 - Fagron held its annual general shareholders meeting where all voting items were approved [1] - The meeting approved Fagron's annual financial statements and a dividend proposal of €0.35 per share for the fiscal year 2024 [2] - The remuneration policy and the appointment of the statutory auditor for the financial years 2025 to 2027 were also approved [2] Group 2 - Ann Desender BV was reappointed as independent non-executive director until the annual general meeting of 2029 [2] - All meeting documents are available on Fagron's website, including the minutes of the meetings [3] - Fagron operates in over 30 countries, focusing on personalized medicine for hospitals, pharmacies, clinics, and patients [4] Group 3 - Fagron NV is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [5] - The operational activities are managed by Fagron BV, headquartered in Rotterdam [5] Group 4 - The dividend calendar includes an ex-dividend date of 19 May 2025, record date of 20 May 2025, and payment date of 21 May 2025 [7]